Breaking News

AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills 

August 1, 2025
Pharmalot Columnist, Senior Writer
Justin Sullivan/Getty Images

STAT+ | AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills

Advocacy groups argued Gilead exploited the federal government by using the benefits of intellectual property to charge ever-higher prices

By Ed Silverman


Opinion: The U.S. needs a revolution to harness the potential of GLP-1s for weight loss

Where is the national plan to facilitate the widespread, safe delivery to eligible Americans of GLP-1s like Novo Nordisk's Wegovy and Eli Lilly's Zepbound?

By Gavin Hart


FDA to stress opioids' risk of overdose, death in new medication safety labels

The decision comes nearly 30 years after initial approval of OxyContin, the now-infamous painkiller sold by Purdue Pharma.

By Lev Facher



Alex Hogan/STAT

STAT+ | Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

By Ed Silverman


What Vinay Prasad's ouster means for biotech and the FDA

STAT reporters discuss how the removal of Vinay Prasad from the FDA will affect the biopharma industry and the agency.

By Elaine Chen, Adam Feuerstein, and Matthew Herper


STAT+ | MAGA influencers take a sudden interest in Medicare Advantage reforms, echoing a dark money group

Pro-Trump influencers trained their fire on Sen. Bill Cassidy after he proposed reforms to Medicare Advantage

By Casey Ross and John Wilkerson


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments